Clinical Trials
9 trialsNCT03700099 2024-04-15
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT04419402 2024-02-07
ENZA-p
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04116775 2022-06-23
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Portland VA Medical Center
Phase 2 Unknown
NCT05212857 2022-03-16
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Fudan University
Phase 2 Unknown
NCT03305224 2021-09-09
CORE-OCU
Osaka City University
Phase 2 Unknown
NCT02525068 2018-08-08
RE-AKT
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT03196388 2018-01-18
ENZART
Fundación Canaria Instituto de Investigación Sanitaria de Canarias
Phase 2 Unknown
NCT02254785 2017-12-06
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
British Columbia Cancer Agency
Phase 2 Unknown
NCT03124615 2017-04-24
EFFECT
Macquarie University, Australia
Phase 2 Unknown